The anti-PD-1 antibody Nivolumab, in 2014 FDA approved for the treatment of advanced melanoma patients, is by the end of 2017and after more than 500 conducted clinical trials now approved for the treatment of nine different tumor entities including e.g., NSCLC, hodgkin lymphoma, squamous head and neck cancer or urothelial cancer[73]. The gene discussed is PDCD1; the disease is melanoma.